This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to determine the optimal immunosuppression and kidney allocation strategies to mitigate the risks of Epstein-Barr virus (EBV) infection for kidney transplant recipients. The $644,770 award, effective May 7, 2025 through April 30, 2030, will support a research consortium of eight large-volume kidney transplant centers to: 1) examine how immunosuppression affects the development of post-transplant lymphoproliferative disorder and EBV infection, 2) evaluate the relationship between immunosuppression and EBV viral kinetics, and 3) model the impact of prioritizing EBV-seronegative kidney transplants for EBV-seronegative recipients on access to transplantation. The research, conducted by the University of Pennsylvania, seeks to identify therapeutic strategies to reduce the risk of cancer for EBV-seronegative kidney transplant recipients who receive organs from EBV-seropositive donors.
Mod # | Description | Reason For Modification | Federal Obligation (Click to sort descending) | Date (Click to sort ascending) |
|---|---|---|---|---|
| Not listed | $644.8k | 5/7/25 |